Clinical effects of Lewy body pathology in cognitively impaired individuals.

"Competing interests None of the authors has any financial interest in the α-syn SAA test. S.P. has acquired research support (for the institution) from ki elements/Alzheimer Drug Discoveries Foundation. In the past 2 years, he has received consultancy/speaker fees from Bioartic, Biogen, Lilly and Roche. O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. M.R., S.H., C.Q., N.M.C., S.D., A.M., S.J., S.B., E.S. and P.P. declare no competing interests."

"Funding Open access funding provided by Lund University."